Diabetic neuropathies: clinical manifestations and current treatment options

被引:117
作者
Vinik, A [1 ]
Ullal, J [1 ]
Parson, HK [1 ]
Casellini, CM [1 ]
机构
[1] Strelitz Diabet Res Inst, Neurovasc Unit, Norfolk, VA 23510 USA
来源
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2006年 / 2卷 / 05期
关键词
diabetes mellitus; diabetic autonomic neuropathy; diabetic neuropathy; pain; treatment;
D O I
10.1038/ncpendmet0142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic neuropathies are a heterogeneous group of disorders that include a wide range of abnormalities. They can be focal or diffuse, proximal or distal, affecting both peripheral and autonomic nervous systems, causing morbidity with significant impact on the quality of life of the person with diabetes, and can result in early death. Distal symmetric polyneuropathy, the most common form of diabetic neuropathy, usually involves small and large nerve Fibers. Small-nerve-fiber neuropathy often presents with pain but without objective signs or electrophysiologic evidence of nerve damage, and is recognized as a component of the impaired glucose tolerance and metabolic syndromes. The greatest risk resulting from small-fiber neuropathy is foot ulceration and subsequent gangrene and amputation. Large-nerve-fiber neuropathies produce numbness, ataxia and uncoordination, impairing activities of daily living and causing falls and fractures. A careful history and detailed physical examination are essential for the diagnosis. Symptomatic therapy has become available and newer and better treatment modalities, based on etiologic factors, are being explored with potential for significant impact on morbidity and mortality. Preventive strategies and patient education still remain key factors in reducing complication rates and mortality.
引用
收藏
页码:269 / 281
页数:13
相关论文
共 78 条
[41]  
Polydefkis M, 2001, Diabetes Technol Ther, V3, P23, DOI 10.1089/152091501750219994
[42]   TOPICAL CAPSAICIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN POSTHERPETIC NEURALGIA, DIABETIC NEUROPATHY AND OSTEOARTHRITIS [J].
RAINS, C ;
BRYSON, HM .
DRUGS & AGING, 1995, 7 (04) :317-328
[43]   Topiramate vs placebo in painful diabetic neuropathy - Analgesic and metabolic effects [J].
Raskin, P ;
Donofrio, PD ;
Rosenthal, NR ;
Hewitt, DJ ;
Jordan, DM ;
Xiang, J ;
Vinik, AI .
NEUROLOGY, 2004, 63 (05) :865-873
[44]   Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF [J].
Rivard, A ;
Silver, M ;
Chen, DF ;
Kearney, M ;
Magner, M ;
Annex, B ;
Peters, K ;
Isner, JM .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (02) :355-363
[45]   Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial [J].
Rosenstock, J ;
Michael, TB ;
LaMoreaux, L ;
Sharma, U .
PAIN, 2004, 110 (03) :628-638
[46]   Uncommon early-onset neuropathy in diabetic patients [J].
Said, G ;
Bigo, A ;
Ameri, A ;
Gayno, JP ;
Elgrably, F ;
Chanson, P ;
Slama, G .
JOURNAL OF NEUROLOGY, 1998, 245 (02) :61-68
[47]   THE EFFECT OF INTENSIVE TREATMENT OF DIABETES ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
SHAMOON, H ;
DUFFY, H ;
FLEISCHER, N ;
ENGEL, S ;
SAENGER, P ;
STRELZYN, M ;
LITWAK, M ;
WYLIEROSETT, J ;
FARKASH, A ;
GEIGER, D ;
ENGEL, H ;
FLEISCHMAN, J ;
POMPI, D ;
GINSBERG, N ;
GLOVER, M ;
BRISMAN, M ;
WALKER, E ;
THOMASHUNIS, A ;
GONZALEZ, J ;
GENUTH, S ;
BROWN, E ;
DAHMS, W ;
PUGSLEY, P ;
MAYER, L ;
KERR, D ;
LANDAU, B ;
SINGERMAN, L ;
RICE, T ;
NOVAK, M ;
SMITHBREWER, S ;
MCCONNELL, J ;
DROTAR, D ;
WOODS, D ;
KATIRGI, B ;
LITVENE, M ;
BROWN, C ;
LUSK, M ;
CAMPBELL, R ;
LACKAYE, M ;
RICHARDSON, M ;
LEVY, B ;
CHANG, S ;
HEINHEINEMANN, M ;
BARRON, S ;
ASTOR, L ;
LEBECK, D ;
BRILLON, D ;
DIAMOND, B ;
VASILASDWOSKIN, A ;
LAURENZI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :977-986
[48]   Demyelinating neuropathy in diabetes mellitus [J].
Sharma, KR ;
Cross, J ;
Farronay, O ;
Ayyar, DR ;
Shebert, RT ;
Bradley, WG .
ARCHIVES OF NEUROLOGY, 2002, 59 (05) :758-765
[49]   THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR PAROXETINE IS EFFECTIVE IN THE TREATMENT OF DIABETIC NEUROPATHY SYMPTOMS [J].
SINDRUP, SH ;
GRAM, LF ;
BROSEN, K ;
ESHOJ, O ;
MOGENSEN, EF .
PAIN, 1990, 42 (02) :135-144
[50]   Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy [J].
Singleton, JR ;
Smith, AG ;
Bromberg, MB .
DIABETES CARE, 2001, 24 (08) :1448-1453